Longevity Health Holdings 주식 (NASDAQ: XAGEW)

에 대한 최신 뉴스 Longevity Health Holdings (NASDAQ:XAGEW) 주식

Longevity Health Holdings Inc is a United States based bio-aesthetics company focused on developing, manufacturing, and marketing cosmetic skincare and haircare products. The company has two cosmetic product lines, Carmell Secretome and Elevai Exosomes, that support skin and hair health.

Longevity Health Holdings, Inc. - Warrant

Longevity Health Holdings Inc

The world&#8217;s biggest hedge funds are making some eyebrow-raising moves and they&#8217;re laser-obsessed with one thing: Big Tech. Based on the most recent 13F filings, institutional investors and hedge funds poured billions into big <a href="https://www.benzinga.com/topic/technology-stocks">tech stocks</a> such as Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) during the last quarter. Even <a href="https://www.benzinga.com/etfs">ETFs themselves</a>, like the iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>), experienced big inflows of more than $21 billion.
So what does it all mean for average investors? Two things:
<ul class="wp-block-list">
<li>The pros remain highly optimistic about tech.</li>
<li>By investing in the right ETFs, individual investors can achieve similar exposure without the hedge fund-sized balance sheet.</li>
</ul>
<h2 class="wp-block-heading">Follow The Smart Money</h2>
While the headlines tend to flow to the likes of BlackRock, Vanguard or Millennium Management, individual investors have access to the same mega-cap tech surge through ETFs. 
Here&#8217;s a rundown of some of those top stocks against recent fund inflows:
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Stock</th>
<th>Top Hedge Fund Buyers</th>
<th>Total Value Bought</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microsoft</td>
<td>Geode, Vanguard, BlackRock</td>
<td>$23.49B</td>
</tr>
<tr>
<td>Amazon </td>
<td>BlackRock, Vanguard, Arrowstreet</td>
<td>$17.75B</td>
</tr>
<tr>
<td>Apple </td>
<td>BlackRock, Geode, Vanguard</td>
<td>$15.77B</td>
</tr>
<tr>
<td>Nvidia </td>
<td>Vanguard, Geode, BlackRock</td>
<td>$14.91B</td>
</tr>
<tr>
<td>Alphabet </td>
<td>Vanguard, BlackRock, Geode</td>
<td>$12.97B</td>
</tr>
<tr>
<td>Meta Platforms </td>
<td>BlackRock, Viking Global</td>
<td>$12.17B</td>
</tr>
<tr>
<td>Tesla</td>
<td>Capstone Investment, Vanguard, BlackRock</td>
<td>$10.12B</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: HedgeFollow</figcaption></figure>
 In the meantime, IVV, an S&amp;P 500 exchange-traded fund, was one of the largest, gaining more than $21.36 billion with Capula Management and Millennium taking the lead.
<h2 class="wp-block-heading">ETFs That Follow The Hedge Fund Tech Bounce</h2>
Here are a few ETFs individual investors can look to access the same themes:
<h3 class="wp-block-heading">IVV, VOO, SPY – Timeless S&amp;P 500 Exposure</h3>
Apart from IVV, the Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) and the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) are filled with the same big-name tech stocks that hedge funds adore. Microsoft, Apple, Nvidia, Amazon, Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), and Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) comprise the heaviest weightings. Notably, VOO has garnered <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/46060843/vanguard-etfs-lead-2025-with-150-billion-inflows-challenging-wall-streets-old-guard">$82 billion in inflows this year</a> as of May 18, indicating strong demand.
<h3 class="wp-block-heading">QQQ, QQQM – Growth-Oriented &amp; Technology-Laden</h3>
Following the Nasdaq-100, Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) and Invesco NASDAQ 100 ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQM#NASDAQ">QQQM</a>) provide leveraged exposure to the largest names in tech, including the leaders of the AI revolution.
<h3 class="wp-block-heading">XLK, VGT &#8211; Technology-Sector Focused </h3>
Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) and Vanguard Information Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VGT#NYSE">VGT</a>). These sector-specific ETFs are best for those seeking a cleaner play in the space. XLK, for example, has more than 40% of its assets in MSFT and AAPL combined.
<h2 class="wp-block-heading">Why The Sprint?</h2>
A number of tailwinds are driving this hedge fund tech wave:
AI Arms Race: Hedge funds are wagering big that the AI revolution is only just beginning.
Earnings Resilience: Big Tech has shown remarkable stability and earnings growth amid rate hikes.
Cloud &amp; Infrastructure Demand: Enterprise spending is ramping back up in areas dominated by Microsoft, Amazon and Alphabet.
Even ETFs like IVV, typically seen as broad-market plays, are riding this trend thanks to their tech-heavy weightings.
Hedge funds weren&#8217;t hoarding Big Tech with deep pockets, so retail investors don&#8217;t have to watch from the sidelines. One can create a diversified, tech-heavy portfolio with a few clicks using ETFs, and a lot less cash.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46081799/3-cybersecurity-etfs-go-malware-free-china-gets-bolder">3 Cybersecurity ETFs To Gain Ground As Threats Go Malware-Free, China Gets Bolder</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Tech

ETFs

AAPL

AMZN

GOOGL

MSFT

NVDA

QQQM

TSLA

Nvidia, Amazon, Tesla Among Tech Stocks Hedge Funds Are Piling Into — Here's How ETFs Like IVV, SPY, VOO Are Riding The Wave

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) with a Buy and maintains $12 price target.

News

Price Target

Reiteration

Analyst Ratings

FEMY

HC Wainwright & Co. Reiterates Buy on Femasys, Maintains $12 Price Target

'Wells Fargo Is Hiring Citi's Muir Paterson To Lead Activism Defense Practice, Source Says'

Small Cap Consumer Research analyst Eric Beder reiterates Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Buy and maintains $23 price target.

Small Cap Consumer Research Reiterates Buy on Guess, Maintains $23 Price Target

FMFC

Trading Halt: Halt status updated at 11:50:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

QuantumScape Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares are trading higher Wednesday after the lithium-metal battery technology company said its Cobra separator process&nbsp;<a href="https://www.benzinga.com/pressreleases/25/06/b46083543/quantumscape-achieves-major-milestone-cobra-separator-process-enters-baseline-production" target="_blank" rel="noreferrer noopener">entered into baseline production</a>.
What Happened: Late Tuesday, QuantumScape announced it reached a milestone in the scale-up of its production capabilities through the integration of its Cobra separator into baseline cell production.
QuantumScape&#8217;s Cobra helps increase production speeds with a smaller footprint than previous ceramic separator manufacturing processes.
&#8220;Cobra is a step-change innovation in ceramic processing, enabling a major improvement in productivity compared to Raptor — which was already a considerable advancement compared to the previous generation,&#8221; said Tim Holme, co-founder and chief technology officer of QuantumScape.
&#8220;This advancement is central to bringing our high-performance solid-state battery platform to market at gigawatt scale.&#8221;
QuantumScape said Cobra is a big step forward in the scaling of solid-state battery production and the commercialization of its next-generation battery technology. The company expects to continue to improve its production speed, efficiency and scalability with Cobra now in place as the new baseline.
QuantumScape shares reached $6.35 in early trading Wednesday before pulling back a bit. QuantumScape has a 52-week high of $9.52 and a 52-week low of $3.40. Analysts have varying forecasts for QuantumScape stock with most holding <a href="https://www.benzinga.com/analyst-stock-ratings">Neutral </a>ratings. The Street-high price target is $8 and the Street-low target is $2. 
QS Price Action: <a href="http://benzinga.com/quote/QS">QuantumScape shares</a> were up 27.4% at $5.52 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/46097418/coreweave-ipo-was-fantastic-entry-point-but-stock-now-a-little-overheated">CoreWeave IPO Was &#8216;Fantastic Entry Point,&#8217; But Stock Now &#8216;A Little Overheated&#8217;</a></li>
</ul>
Photo: courtesy of QuantumScape.

Movers

QuantumScape Stock Is Soaring Wednesday: Here's Why

<a href="https://www.youtube.com/watch?v=6oJb0QSEwpo">https://www.youtube.com/watch?v=6oJb0QSEwpo</a>
&nbsp;

Macro Economic Events

Economics

Federal Reserve

Fed Chair Powell Says In High Uncertainty As Now, Want To Take Signal From Real Data, Not Be So Brave About Forecasts; Don't Want To Give A Lot Of Forward Guidance; Makes Sense To Move More Slowly When There Is More Uncertainty, In Most Cases; On AI, Says Potential To Make Dramatic Changes Is Very Clear, But Uncertainty About Timing; U.S. Economy Is Performing Better Than Other Countries, Which Implies Higher Interest Rates

Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) has outperformed the market over the past 5 years by 4.95% on an annualized basis producing an average annual return of 19.46%. Currently, Lennox Intl has a market capitalization of $20.94 billion. 
Buying $1000 In LII: If an investor had bought $1000 of LII stock 5 years ago, it would be worth $2,463.77 today based on a price of $590.00 for LII at the time of writing.
<h3>Lennox Intl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750866341_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Lennox Intl Stock In The Last 5 Years

HIMS just suffered the biggest single-day drop in its trading history… a&nbsp;HISTORIC 34.53%&nbsp;pull back. And CEO Andrew Dudum isn't backing down.
<figure class="wp-block-image"><img decoding="async" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/9fa7bdc7-12be-46d8-adac-cd16ac340da5/image.png?t=1750815277" alt="" /></figure>
Hims &amp; Hers Health&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) 
After $NVO Novo Nordisk abruptly terminated their partnership, citing "deceptive marketing," Hims &amp; Hers fired back with confidence… saying they'll&nbsp;continue offering compounded GLP-1 meds&nbsp;for weight loss at accessible prices.
In interviews and public posts, Dudum called the termination "misleading" and pulled back the curtain on&nbsp;months of rising tension behind the scenes. According to him, Novo had been&nbsp;pressuring HIMS to direct more patients toward Wegovy&nbsp;instead of compounded options, which HIMS believes remain FDA-compliant for personalized medical use.
"They were pushing us to a degree that was uncomfortable. They've been losing a tremendous amount of market share… and I think they're just under real financial strain to try to drive sales."
&#8211;HIMS CEO Andrew Dudum
This isn't just a licensing dispute… it's a glimpse into the&nbsp;power struggle between upstarts and Big Pharma. Dudum framed it as part of a broader trend: legacy giants trying to&nbsp;retain control over pricing, distribution, and exclusivity, even if it means cutting ties with companies offering cheaper, legal alternatives.
<figure class="wp-block-image"><img decoding="async" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/27aa425e-957e-4572-812d-4537e99229d6/image.png?t=1750815395" alt="" /></figure>
The timing is also interesting. GLP-1s are&nbsp;Novo Nordisk's biggest and fastest-growing revenue stream, and competition is heating up. Eli Lilly's Zepbound is gaining traction, compounded access is expanding, and supply issues are easing. In that context, this move feels more like&nbsp;margin protection than public safety.
Was Novo looking for an exit all along? Or is this a calculated strike against a fast-growing competitor? Either way, HIMS isn't backing off. And with a proven track record of affordability, tech-driven care, and massive demand for GLP-1s… this drop may turn into opportunity.
&#x2A;&#x2A;
If you're enjoying the article so far (and we know you are), here's your chance to see exactly what paid subscribers get.
Most Americans are buried in debt, yet over 60 billionaires were minted during COVID.
What separates them?&nbsp;Financial literacy.
Our CEO is a former Goldman Sachs analyst who's spent 8,000+ hours teaching real-world money strategy.
Each week, subscribers get:
Deep dives into stocks and sectors
Step-by-step guides to building wealth
Simple breakdowns of complex market trends
This week's issue is&nbsp;free, so you can see for yourself.
In a world of rising debt, inflation, and geopolitical instability, learning how to protect and grow your money isn't optional anymore.
&#x1f447; Preview today's premium edition, then decide if $9/month is worth it.
<h3 class="wp-block-heading">BTCL Swing Trade Update</h3>
Our&nbsp;<a href="https://stocktwits.com/symbol/BTCL?utm_source=marketmadness-newsletter.beehiiv.com&amp;utm_medium=referral&amp;utm_campaign=after-it-s-biggest-drop-ever-is-hims-a-buy" target="_blank" rel="noreferrer noopener">$BTCL ( ▲ 3.65% )</a>&nbsp;swing trade is performing nicely following the recent escalation in the Middle East. We entered at&nbsp;$51.00, and with the price now around&nbsp;$52.45, we're currently up&nbsp;+2.84%&nbsp;on the position.
<figure class="wp-block-image"><img decoding="async" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/30d5e30c-bc97-456c-a4e2-1102926ba83c/image.png?t=1750816929" alt="" /></figure>
Here's the current plan:
<ul class="wp-block-list">
<li>First target:&nbsp;$54.50 → Take off&nbsp;50%&nbsp;of the position</li>
<li>Second target:&nbsp;$57.13 → Take off another&nbsp;35%</li>
<li>Runners:&nbsp;Leave the remaining&nbsp;15%&nbsp;to ride momentum</li>
</ul>
And if things pull back?
We&nbsp;don't let green turn red… if price retraces back to&nbsp;$51.00, we'll close the position at breakeven.
<figure class="wp-block-image"><img decoding="async" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/e2f4f4aa-231b-4dae-9828-71385b3bcc25/image.png?t=1750816847" alt="" /></figure>
Momentum is building. Bitcoin is setting up well while&nbsp;<a href="https://stocktwits.com/symbol/QQQ?utm_source=marketmadness-newsletter.beehiiv.com&amp;utm_medium=referral&amp;utm_campaign=after-it-s-biggest-drop-ever-is-hims-a-buy" target="_blank" rel="noreferrer noopener">$QQQ ( ▲ 0.21% )</a>&nbsp;just made a&nbsp;new closing ATH. We believe&nbsp;<a href="https://stocktwits.com/symbol/BTC?utm_source=marketmadness-newsletter.beehiiv.com&amp;utm_medium=referral&amp;utm_campaign=after-it-s-biggest-drop-ever-is-hims-a-buy" target="_blank" rel="noreferrer noopener">$BTC ( ▲ 2.2% )</a>&nbsp;could be next, which would put this trade in a very strong spot.
Stay tuned for updates… and make sure to manage risk in case we hit targets before Friday's newsletter.
Thanks for reading!
&#x2A;&#x2A;

Equities

Long Ideas

Opinion

Markets

Hims & Hers Health, Inc. Class A Common Stock

HIMS

After Its Biggest Drop Ever...Is HIMS A Buy?

Fed Chair Powell Says Fed Modernization Of Discount Window Will Take Some Time; Going Back To Old CRA Rules; U.S. Labor Market Solid, Economy Growing, Inflation In A Pretty Good Place; Watching Labor Market Very Closely; Low Hiring Rate Means That If We Saw Layoffs Go Up, Unemployment Rate Would Rise Quickly

CleanSpark Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) shares are trading higher by 4.43% to $10.46 Wednesday morning, fueled by positive analyst sentiment and recent operational achievements.
What To Know: The surge follows an update from Chardan Capital, with analyst James McIlree reiterating a &#8220;Buy&#8221; rating and a $20 price target on the Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining company.
This upward momentum builds on Tuesday&#8217;s gains, which were largely driven by a rise in Bitcoin&#8217;s price. The <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46091840/bitcoin-ethereum-xrp-dogecoin-hold-gains">cryptocurrency&#8217;s rebound</a> above the $100,000 level provided a significant lift to crypto-related stocks. 
However, CleanSpark outpaced many of its peers after announcing it had <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46078810/bitcoin-mining-stock-cleanspark-is-surging-tuesday-whats-fueling-the-momentum">successfully reached</a> its mid-year target of a 50 exahash per second (EH/s) operational hashrate.
Zach Bradford, CEO of CleanSpark, called the milestone a result of the company&#8217;s strategy of building and operating its own infrastructure, ensuring &#8220;control, resilience and scalability.&#8221;
Read Also: <a href="https://www.benzinga.com/pressreleases/25/06/n46070322/cleanspark-reaches-50-ehs-milestone-escape-velocity-in-action">CleanSpark Reaches 50 EH/s Milestone; Escape Velocity in Action</a>
Additionally, in its latest operational update, CleanSpark announced it mined 694 bitcoin in May, a 10% increase month-over-month. The company concluded the period with 12,502 bitcoin in its treasury after selling 293.5 bitcoin.
Analyst Coverage: According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>,&nbsp;earlier in June, JP Morgan signaled renewed confidence by raising its price target to $14 from $12, reversing a target cut it had made in March.
Throughout the year, sentiment has been positive, highlighted by a February initiation from Needham with a &#8220;Buy&#8221; rating and a $20 target, while HC Wainwright &amp; Co. has consistently reiterated its &#8220;Buy&#8221; rating with one of the highest price targets on the street at $27.
Per Benzinga pro data, CLSK has a 52-week high of $20.49 and a 52-week low of $6.46.
Read Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46094408/how-bitcoin-is-maturing-to-a-global-liquidity-asset-report">How Bitcoin Is Maturing To A Global Liquidity Asset: Report</a>
<h2 class="wp-block-heading">How To Buy CLSK Stock</h2>
By now you're likely curious about how to participate in the market for Cleanspark &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Cleanspark, which is trading at $10.57 as of publishing time, $100 would buy you 9.46 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Image: Shutterstock

$BTC

CLSK

Bitcoin Mining Stock CleanSpark (CLSK) Is Surging Wednesday: What's Going On?

WIIM

BP shares are trading higher after the Wall Street Journal reported Shell is in early talks to acquire the company.

SHEL

Shell shares are trading lower after a Wall Street Journal report said the company is in early talks to acquire BP.

<a href="https://www.wsj.com/business/energy-oil/shell-in-early-talks-to-acquire-rival-bp-2233591a" title="https://www.wsj.com/business/energy-oil/shell-in-early-talks-to-acquire-rival-bp-2233591a">https://www.wsj.com/business/energy-oil/shell-in-early-talks-to-acquire-rival-bp-2233591a</a>

'Shell in Early Talks to Acquire Rival BP; A Deal For BP, Worth Roughly $80B, Would Be A Landmark Combination Of Two Supermajor Oil Companies' - WSJ

Winnebago Industries shares are trading lower after the company reported Q3 financial results and cut its FY25 guidance below estimates.

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares are hitting new all-time highs on Wednesday. Here&#8217;s a look at what&#8217;s <a href="https://www.benzinga.com/news/space/25/06/46090791/us-tests-radar-that-could-help-trumps-golden-dome-detect-missiles-over-1200-miles-report">fueling the momentum</a>.
What To Know: Palantir shares have risen more than 500% over the past year and are now up approximately 93% year-to-date. 
Much of the momentum has been driven by the company&#8217;s positioning in the AI space.&nbsp;The stock also appeared to get a lift more recently from the Israel-Iran conflict. Palantir has several government contracts and has seen an acceleration since President Donald Trump took office, securing <a href="https://www.benzinga.com/news/contracts/25/05/45702431/palantir-stock-gains-as-trump-expands-companys-role-in-us-government-agencies">more than $113 million</a>&nbsp;in contracts. Palantir was also awarded a $795 million contract modification by the U.S. Army for its Maven Smart System&nbsp;in May.
As defense budgets increasingly incorporate AI, Palantir could be a potential beneficiary of heightened geopolitical tensions. Palantir signed a strategic agreement with the Israeli Defense Ministry to support war efforts last year, <a href="https://www.palantir.com/assets/xrfr7uokpv1b/3MuEeA8MLbLDAyxixTsiIe/9e4a11a7fb058554a8a1e3cd83e31c09/C134184_finaleprint.pdf">per</a> Bloomberg.
Even as Palantir shares continue to climb to new highs, some analysts believe there could be more room to run. Loop Capital analyst Mark Schappel maintained Palantir with a Buy and raised the price target from&nbsp;$130&nbsp;to&nbsp;$155 earlier this month. At the end of May, Wedbush's Dan Ives predicted that Palantir shares will more than triple in two to three years to reach a $1 trillion market cap valuation, or approximately $427 per share.
"[Alex] Karp, he's playing chess, others are playing checkers. And I think you are starting to realize more and more in government, enterprise, and that's why you cannot talk AI revolution without saying Palantir,&#8221; Ives said in a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45655507/tech-analyst-expects-palantir-stock-to-rise-above-400-as-ai-revolution-kicks-into-gear">CNBC</a> interview. 
Palantir has a strong momentum score of 99, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> data. The company beat analyst estimates in the first quarter as U.S. Commercial revenue grew 71% year-over-year and U.S. Government revenue climbed 45%. 
Palantir also guided for second-quarter revenue in the range of $934 million to $938 million versus estimates of $899.12 million, and raised its full-year outlook. The company said in its earnings release that it&#8217;s experiencing &#8220;surging and ferocious growth.&#8221;
PLTR Price Action: Palantir shares traded as high as $147.67 on Wednesday, marking new all-time highs. The stock was up 0.18% at $142.94 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Palantir has an RSI of 66, per Benzinga <a href="https://www.benzinga.com/quote/PLTR">data</a>. A stock is generally considered overbought when its relative strength rises above 70. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46090043/trump-advisor-stephen-miller-reportedly-holds-stake-worth-millions-in-ice-contractor-palantir-he-could-easily-have-a-direct-and-predictable-impact">Trump Advisor Stephen Miller Reportedly Holds Stake Worth Millions In ICE Contractor Palantir: &#8216;He Could Easily&#8230;Have A Direct And Predictable Impact&#8217;</a></li>
</ul>
Photo: slyellow/Shutterstock.

PLTR

Palantir Stock Hits All-Time High: What's Going On?

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is continuing its remarkable run Wednesday, with shares climbing 2.6% to $151.74, near a new all-time high. The stock&#8217;s recent run completes a full recovery from a 17% drop in January, initially sparked by fears that China&#8217;s DeepSeek AI <a href="https://www.benzinga.com/markets/tech/25/06/46062695/nvidia-deepseek-ai-chips-us-china-military-news">could challenge</a> Nvidia&#8217;s market dominance.
What To Know: Nvidia&#8217;s rebound in recent weeks has been fueled by a significant easing in U.S.-China trade tensions and a stellar first-quarter earnings report on May 28. 
The company announced earnings per share of 81 cents on a staggering $44.06 billion in revenue, a 69% year-over-year increase, <a href="https://www.benzinga.com/markets/tech/25/06/46058862/nvidia-intel-chip-stocks-ai-valuation-revenue">blowing past</a> analyst expectations and reaffirming its leadership in the AI chip sector.
Adding to the bullish sentiment, Nvidia&#8217;s stock is on the verge of a &#8220;<a href="https://www.benzinga.com/markets/tech/25/06/46081553/nvidia-stock-forecast-trump-china-golden-cross-ai">golden cross</a>,&#8221; a technical pattern where the 50-day moving average surpasses the 200-day average, often signaling a sustained uptrend. Historically, this pattern has preceded massive rallies in Nvidia&#8217;s stock, with past occurrences leading to triple and even quadruple-digit percentage gains.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/06/46072105/hcltech-amd-partner-to-power-next-gen-enterprise-ai-and-cloud-adoption">HCLTech, AMD Partner To Power Next-Gen Enterprise AI And Cloud Adoption</a>
Despite recent allegations that DeepSeek has been supplying Nvidia&#8217;s advanced chips to China&#8217;s military, circumventing U.S. export controls, investors remain focused on the company&#8217;s explosive growth, which continues to vastly <a href="https://www.benzinga.com/markets/tech/25/06/46058862/nvidia-intel-chip-stocks-ai-valuation-revenue">outpace competitors</a> like Intel Corp.
Analyst Updates: Following its strong earnings report, Wall Street has shown <a href="https://www.benzinga.com/quote/NVDA/analyst-ratings">overwhelming confidence</a> in Nvidia&#8217;s continued growth. In a flurry of updates on May 29, numerous firms reiterated their positive ratings and raised price targets. 
Notably, Truist Securities increased its target to $210, and Rosenblatt lifted its target to $200. The bullish sentiment has continued into June, with Barclays raising its price target to $200 on June 17 while maintaining an &#8220;Overweight&#8221; rating. 
The vast majority of analysts maintain a &#8220;Buy&#8221; or equivalent rating, with many price targets suggesting a potential upside of 15% to over 35% from its current highs.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NVDA has a 52-week high of $153.13 and a 52-week low of $86.62.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/06/46069690/alibaba-accelerates-global-ai-push-targets-overseas-data-centers">Alibaba Accelerates Global AI Push, Targets Overseas Data Centers</a>
<h2 class="wp-block-heading">How To Buy NVDA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in NVIDIA&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

Nvidia Stock Soars Near Record High: What's Driving the Rally?

JP Morgan analyst Alexei Gogolev maintains Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) with a Overweight and raises the price target from $271 to $288.

GWRE

JP Morgan Maintains Overweight on Guidewire Software, Raises Price Target to $288

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and maintains $17 price target.

BCRX

Needham Reiterates Buy on BioCryst Pharma, Maintains $17 Price Target

Shares of Carnival Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) were trading lower on Wednesday, despite the company on Tuesday reporting <a href="https://www.benzinga.com/markets/earnings/25/06/46076919/carnival-sails-past-q2-estimates-raises-full-year-outlook-on-strong-demand">upbeat fiscal second-quarter results</a>.
The announcement came amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
Goldman Sachs On Carnival
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/647713f84d196600013124ad/lizzie-dove">Analyst Lizzie Dove</a> maintained a Buy rating, while raising the price target from $31 to $33.
Carnival's fiscal second-quarter results came "significantly" ahead of expectations and the upside flowed through to its 2025 guidance, Dove said in the note. The company&#8217;s indication that it is accelerating trends into May and June suggests the guidance is "somewhat conservative," she added.
The analyst continued to cite Carnival as among her top picks. "While the macro/geopolitical environment remains murky, CCL's exposure to primarily local Europe exposure and higher exposure to drive-to/shorter itineraries from the U.S. should provide some buffer to these headwinds," she further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Stifel On Carnival
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e84a1b9387cff00014945da/steven-wieczynski">Analyst Steven M. Wieczynski</a> reaffirmed a Buy rating and raised the price target from $33 to $34.
Carnival reported gross and net revenue of $6.3 billion and $4.9 billion, ahead of the consensus of $6.2 billion and $4.8 billion, respectively, Wieczynski said. Management raised their full-year guidance for adjusted earnings from $1.83 per share to $1.97 per share and for adjusted EBITDA from $6.7 billion to $6.9 billion, he added.
While investors have been nervous about cruise demand going into 2026, given the highly uncertain consumer spending environment, Carnival's latest commentary should help alleviate those concerns, especially since the company's 2026 bookings are close to record levels, the analyst stated. Investors still seem to be "overlooking the significant FCF generation that is currently being produced which will help delever CCL's balance sheet," he further wrote.
CCL Price Action: Shares of Carnival were down 0.9% to $25.46 at the time of publication on Wednesday.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46096528/nasdaq-100-record-highs-rally-historical-performance">Nasdaq 100 Hits Record Highs After 30% Rally: History Suggests It&#8217;s Not Done Yet</a></li>
</ul>
Photo: Shutterstock

Comments

Longevity Health Holdings

뉴스

에 대한 최신 뉴스 Longevity Health Holdings (NASDAQ:XAGEW) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌